Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Immunomonitoring Lymphocyte Subpopulations in Multiple Sclerosis Patients

Aina Teniente-Serra  1   2 , Cristina Ramo-Tello  3 , Eva M. Martinez-Caceres  1   2
Ian S. Zagon  1 , Patricia J. McLaughlin  1
, editors.
In: Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet]. Brisbane (AU): Codon Publications; 2017 Nov 27. Chapter 9.
Affiliations
Free Books & Documents
Review

Immunomonitoring Lymphocyte Subpopulations in Multiple Sclerosis Patients

Aina Teniente-Serra et al.
Free Books & Documents

Excerpt

Advances in the understanding of pathogenic mechanisms of diseases have led to the defining of new biomarkers for diagnosis, prognosis, and therapy response. In this context, flow cytometry has been positioned as one of the most useful technologies for monitoring immune-mediated diseases, such as multiple sclerosis (MS), allowing a detailed analysis of lymphocyte subpopulations in peripheral blood. The autoimmune inflammatory response in MS results in changes in lymphocyte subpopulations that might be useful as surrogate markers for the evaluation of disease activity, progression, and monitoring of therapy response. This chapter discusses the role of T-lymphocyte and B-lymphocyte subpopulations in MS pathogenesis, the effect of MS treatments on these subsets, and their potential usefulness as biomarkers of treatment response.

PubMed Disclaimer

References

    1. Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. The problems and promises of research into human immunology and autoimmune disease. Nat Med. 2012 Jan;18(1):48–53. doi: 10.1038/nm.2626. - DOI - PubMed
    1. Willis JC, Lord GM. Immune biomarkers: The promises and pitfalls of personalized medicine. Nat Rev Immunol. 2015 May;15(5):323–9. doi: 10.1038/nri3820. - DOI - PubMed
    1. Hernandez-Fuentes MP, Lechler RI. A “biomarker signature” for tolerance in transplantation. Nat Rev Nephrol. 2010 Oct;6(10):606–13. doi: 10.1038/nrneph.2010.112. - DOI - PubMed
    1. Maecker HT, Nolan GP, Fathman CG. New technologies for autoimmune disease monitoring. Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):322–8. doi: 10.1097/MED.0b013e32833ada91. - DOI - PMC - PubMed
    1. Chattopadhyay PK, Roederer M. Cytometry: Today’s technology and tomorrow’s horizons. Methods. 2012 Jul;57(3):251–8. doi: 10.1016/j.ymeth.2012.02.009. - DOI - PMC - PubMed

LinkOut - more resources